NCT00431275View on ClinicalTrials.gov

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Melanoma
Interventions
DRUG

CP-675,206

CP-675,206 15 mg/kg iv single dose on Day 1

DRUG

CP-675,206

CP-675,206 15 mg/kg iv single dose on Day 1

Trial Locations (8)

10016

Research Site, New York

15213

Research Site, Pittsburgh

19104

Research Site, Philadelphia

30322

Research Site, Atlanta

33140

Research Site, Miami Beach

33180

Research Site, Aventura

80010

Research Site, Aurora

85260

Research Site, Scottsdale

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY